Company: XOMAP
Filing Date: 2025-09-23
Form Type: 8-K
Source: 0001193125-25-213583
Chunk: 0

Company: XOMA Royalty Corp
Filing Date: 2025-09-23
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item 2.01      Completion of Acquisition or Disposition of Assets.  

As previously disclosed, XOMA Royalty Corporation (“ XOMA”) entered into an Agreement and Plan of Merger, dated August 4, 2025 (the “ Merger Agreement”), with HilleVax, Inc., a Delaware corporation (“ HilleVax”), and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA (“ Merger Sub”).

Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on September 16, 2025, XOMA and Merger Sub completed a tender offer to purchase all of HilleVax’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Shares”), for a price per Share of (i) $1.95 in cash (the “ Cash Amount”), payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferablecontractual contingent value right (each, a “ CVR”), which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement, dated September 17, 2025 (the “ CVR Agreement”), by and among XOMA, Merger Sub, Broadridge Corporate Issuer Solutions, LLC (“ Broadridge”), a Pennsylvania limited liability company, as rights agent, and Dr. Robert Hershberg, solely in his capacity as the initial representative, agent and attorney-in-factof the Holders (as defined therein), issuable without interest (such amount, the “ CVR Amount,” and together with the Cash Amount, the “ Offer Price”), all upon the terms and subject to the conditions described in the Offer to Purchase, dated August 18, 2025 (together with any amendments or supplements thereto, the “ Offer to Purchase”), and in the related Letter of Transmittal (together with any amendments or supplements thereto, the “ Letter of Transmittal,” which, together with the Offer to Purchase, constituted the “ Offer”), copies of which are attached to the Tender Offer Statement on Schedule TO filed with the United States Securities and Exchange Commission (the “ SEC”) on August 18, 2025 as exhibits (a)(1)(A) and (a)(1)(B), respectively.

The Offer and related withdrawal rights expired as scheduled,